International Support Group
Home Hospitals Doctors How It Works Blog FAQs
Get A Quote
HAEMATOLOGY & STEM CELL THERAPY Procedure

Bone marrow transplant (allogeneic — related & MUD) Clinical Guide

Allogeneic HSCT infuses healthy stem cells from a matched sibling donor (MSD) or 10/10 matched unrelated donor (MUD) from global registries to generate a Graft-Versus-Leukemia (GVL) effect curing acute leukemia and severe aplastic anemia.

Bone marrow transplant (allogeneic — related & MUD)
Bone marrow transplant (allogeneic — related & MUD)

Clinical Overview & Disease Information

Allogeneic HSCT infuses healthy stem cells from a matched sibling donor (MSD) or 10/10 matched unrelated donor (MUD) from global registries to generate a Graft-Versus-Leukemia (GVL) effect curing acute leukemia and severe aplastic anemia.

Signs & Symptoms

Early Symptoms
  • Unexplained severe fatigue, pallor, and dyspnea on exertion
  • Frequent unprovoked bruising, petechiae, or gum bleeding
  • Unexplained low-grade fever, night sweats, or unintentional weight loss
Common Symptoms
  • Persistent painful lymphadenopathy (swollen neck/axillary nodes)
  • Severe bone pain or pathological fractures (Multiple Myeloma)
  • Recurrent painful vaso-occlusive crises or severe joint hemarthrosis
  • Splenomegaly and mucosal bleeding
Emergency Symptoms
  • Neutropenic fever > 100.4°F (38.3°C) during chemotherapy
  • Spontaneous intracranial or retroperitoneal hemorrhage
  • Acute chest syndrome in Sickle Cell Anemia

Causes & Risk Factors

Primary Causes & Etiology

  • Clonal hematopoietic stem cell mutations (JAK2, FLT3, NPM1, BCR-ABL1, TP53)
  • Genetic hemoglobinopathies (Beta-Thalassemia Major, Sickle Cell Disease)
  • Immune-mediated marrow aplasia or platelet autoantibodies
  • Factor VIII / IX genetic deficiency (X-linked Hemophilia A & B)

Who is at Higher Risk?

  • Patients with diagnosed hematological malignancies or inherited blood disorders
  • Individuals requiring bone marrow stem cell transplantation or targeted cellular immunotherapies

Diagnostic Evaluation & Testing

Diagnostic Test Clinical Purpose / What It Shows
High-Resolution 10-Allele HLA-A, B, C, DRB1, DQB1 Tissue Typing & Chimerism Testing Comprehensive bone marrow aspirate cytogenetics, flow cytometry immunophenotyping, and molecular NGS testing

Comprehensive Treatment Options

10/10 HLA-Matched Sibling / Matched Unrelated Donor Allogeneic Stem Cell Infusion

Advanced targeted cellular therapy, stem cell transplantation, or biologic intervention.

Key Advantages:
Curative potential for previously fatal blood cancers and hemoglobinopathies
Targeted precision immunotherapies sparing healthy tissue
High-dose stem cell rescue capabilities

Myeloablative / Reduced Intensity Conditioning (RIC) Fludarabine-Busulfan Regimen

Multidisciplinary conditioning chemotherapy or chronic management protocol.

Recommended For:
Relapsed or refractory hematological malignancies
High-risk cytogenetic or molecular profile

Advanced Medical Technologies Available in Partner Hospitals

Autologous & Allogeneic BMT CAR-T Cell Therapy High-Resolution 10-Allele HLA Typing Flow Cytometry CD34+

Possible Complications If Untreated

Graft-Versus-Host Disease (GVHD)
Cytokine Release Syndrome (CRS) / ICANS
Febrile neutropenia and opportunistic fungal infections

Recovery Timeline, Diet & Lifestyle Care

Recovery Timeline

Procedure / Stage Expected Recovery Duration
HEPA-Filtered BMT Isolation Unit 14 to 21 days
Neutrophil & Platelet Engraftment 21 to 28 days
Outpatient Immunosuppression Taper 3 to 6 months

Recommended Post-Treatment Diet

  • Strict neutropenic clean diet (well-cooked food, no raw fruits/salads)
  • Sterile bottled water
  • High protein nutrition

Essential Lifestyle Changes

  • Wear N95 mask in public and avoid crowds during immunosuppression
  • Take Tacrolimus/Acyclovir at exact 12-hour intervals
  • Daily temperature and blood pressure logging
When to Contact a Doctor Urgently:
Fever > 100.4°F (38°C)
New skin rash or severe watery diarrhea (GVHD warning)
Bleeding or petechiae

Prevention & Long-Term Health

Genetic counseling and prenatal screening for Thalassemia & Sickle Cell
Complete vaccination protocol post-BMT

Frequently Asked Questions

What is the success rate of Bone marrow transplant (allogeneic — related & MUD)?

Cure rates for BMT and CAR-T cell therapy exceed 75-90% in JCI accredited hematology centers of excellence under experienced transplant teams.

Top Recommended Specialists Available

Dr. Gaurav Dixit

Dr. Gaurav Dixit

Head – Haematology Oncology & Bone Marrow Transplant (Unit II)

View Doctor Profile →
Dr. Rahul Naithani

Dr. Rahul Naithani

Chief - Hematology, Oncology & Bone Marrow Transplant

View Doctor Profile →
Dr. Mukesh Patekar

Dr. Mukesh Patekar

Unit Head - Medical Oncology

View Doctor Profile →
Dr. Vineeta Raina

Dr. Vineeta Raina

Sr. Consultant - Pathology & Hematopathology

View Doctor Profile →
Dr. Arun Singh Danewa

Dr. Arun Singh Danewa

Senior Consultant – Pediatric-Haemato-Oncology & Bone Marrow Transplant (Unit II)

View Doctor Profile →

Global Cost Comparison Matrix

Procedure USA (Avg) India (ISG) Turkey (Avg) Thailand (Avg)
Bone marrow transplant (allogeneic — related & MUD) $180,000 $26,000 $45,000 $50,000

Request Free Clinical Opinion & Cost Estimate

Upload your diagnostic reports or medical summary for a free review by leading specialists within 24-48 hours.

Get Free Treatment Estimate

Commonly Prescribed Medications

  • Tacrolimus 1mg twice daily
  • Mycophenolate Mofetil 500mg
  • Post-Transplant Cyclophosphamide (PTCy 50mg/kg)
  • Posaconazole

International Patient Guide

Estimated Stay in India:
HLA Typing & Bone Marrow Evaluation 3 - 5 days
BMT / CAR-T Inpatient Isolation 21 - 30 days
Engraftment Check & Return Flight 45 - 60 days total stay
Documents to Bring:
  • Valid Passport & Medical Visa
  • Bone Marrow Biopsy & HLA Tissue Typing CDs
  • Hematology Specialist Summary